The latest acquisitions news from the healthcare sector;
HAS Healthcare Advanced Synthesis SA (“HAS”), a leading international developer and producer of active pharmaceutical ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs), and anticancer compounds, today announces the planned acquisition of Cerbios-Pharma SA (“Cerbios”), a globally recognised manufacturer of chemical and biological APIs, including in the fast-growing area of antibody drug conjugates (ADCs). Both companies are based in Switzerland and sell globally.
The acquisition is supported by 65 Equity Partners, a global investment firm dedicated to supporting family-owned businesses, founders, and entrepreneurs. As part of the transaction, 65 Equity Partners becomes a c.40% shareholder alongside the Braglia family who retain majority ownership.
The combination of HAS and Cerbios creates a highly complementary and integrated leader in the Contract Development and Manufacturing Organization (CDMO) industry. Together, the two companies bring extensive production, chemical and biological expertise, technical excellence, and a broader range of services to meet the evolving needs of the global pharmaceutical industry.
With the strategic backing of 65 Equity Partners, the new Group is uniquely positioned for growth in an industry underpinned by strong structural tailwinds. These include rising demand for complex therapies and continued innovation in drug development across oncology, neurology, endocrinology, dermatology, rare diseases, gastrointestinal and other key therapeutic areas.
Importantly, HAS and Cerbios will continue to be guided by the strong corporate culture and family ownership values that have long defined both companies, with a firm commitment to Switzerland’s Ticino region remaining at its core.
The operation represents a pivotal moment for the growth of HAS and Cerbios and reflects the continuous investments that have been made to ensure excellence and technological development.
Be the first to comment